Affinivax Announces $226 Million Series C Financing to Advance Its Pipeline of Novel MAPS™ Vaccines Targeting Infectious Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3oxhvrI
via IFTTT